Search

In the interest of helping simplify options trading for beginners, here are a few strategies (and Cabot services) to consider starting with.

Four of the stocks in our portfolio reported first quarter results today. There are two rating changes.

Marijuana is the fastest-growing industry in America. And marijuana stocks are growing even faster. Here’s how to invest in this red-hot sector.

Note from Cabot Wealth Advisory Editor Elyse Andrews: Occasionally, we bring you articles from outside sources that we feel you will be interested in and benefit from. Today, we have an article from Nathan Slaughter, Chief Investment Strategist of the Half-Priced Stocks newsletter at StreetAuthority, about why you should invest in the “Best-Managed Bank in America.” I hope you enjoy it!

Airline stocks surged in June and are having a solid July, but which domestic carriers belong in first class and which are stuck in the jump seat?

The market’s nascent bounce two weeks ago has morphed into a very impressive rally, led by a gaggle of growth stocks that are acting better than they have since late last year and early 2021. We’re not completely out of the woods, and earnings season can always throw a wrench into things, but there’s no question the evidence has improved. We’re putting some more money to work tonight, averaging up in one name and adding a familiar face back to the portfolio as well.

The Cabot Undervalued Stocks Advisor is on vacation this week, recharging the batteries for what could be a very interesting September and fourth quarter in the financial markets. As such, this week’s edition will be abbreviated in length, although we include our Cisco earnings commentary in full.

The U.S. stock market rebounded on Tuesday, following testimony from Chair Powell at his Senate confirmation hearing. Investors liked what he said, implying that the three anticipated quarter-point rate increases, which could start in March, would likely be enough to quell inflation (along with a hoped-for return to normal supply conditions).

Earnings reports from two recommended companies were mildly encouraging. There was very little news on other recommended companies. We note our recent Sell recommendation that produced a 41% return since our September 2021 Buy recommendation. We also comment on an emerging macro concept useful for value investors.

More color on our recent sale that generated a 40% gain since September and comments on other recommended stocks.

Earnings updates from three recommended companies as well as comments on other recommended stocks.

Current Market Outlook


Most major indexes have finally taken a bit of a breather during the past few trading days, with the 200-day moving average providing a bit of logical resistance. So far, the damage has been very limited and, in fact, many leading growth stocks actually hit new highs today. Without predicting any specific path, the big prior run, overhead resistance and still-iffy longer-term trend probably means more choppiness and potholes are on the way, especially as earnings season continues. But the overall evidence (which, by the way, includes a lack of meaningful pullbacks so far) continues to impress. We still think the next big move from here is up, but be sure to pick your spots (and your stocks) on the buy side, and practice patience with your strongest performers, giving them a chance to continue advancing.

This week’s list sports a bunch of recent earnings winners from a variety of industries. Our Top Pick is Array Biopharma (ARRY), which has shown fantastic accumulation pre- and post-earnings as it lifted to all-time highs.

Stock Name	Price	Buy Range	Loss Limit
Array Biopharma (ARRY)	46.35	20-21.5	17.5-18.5
Chipotle Mexican Grill (CMG)	773.32	575-605	530-540
Columbia Sportswear (COLM)	102.15	103.5-107.5	95-97
Glaukos Corp. (GKOS)	67.84	65.5-68	59-61
Kirkland Lake Gold (KL)	51.30	30-32	27-28.5
LPL Financial Holdings (LPLA)	85.22	74.5-77	67.5-69.5
Palo Alto Networks (PANW)	236.92	213-220	193-199
Paycom Software (PAYC)	0.00	163-170	146-151
Spirit AeroSystems (SPR)	92.54	90-93	83.5-85
Zendesk (ZEN)	82.19	73.5-77	65-67

The market remains in a correction, and with the intermediate-term trend pointed down, we’re still advising a cautious stance. That said, we do think the pieces are in place for a new advance, from positive longer-term evidence, a big dip in sentiment and bullish action from many leading growth stocks.
In tonight’s issue we review all of our stocks, fine tune our watch list and we also look at the medical sector, which we think could be a leadership area going forward for a few reasons.

Current Market Outlook


The market’s meltdown today cracked the intermediate-term uptrend that got going back in January, with all major indexes (and many leading stocks) closing well below their 50-day lines today. Big picture, we still see this as a bull market, so we’re still OK holding most of your shares in your strong, profitable stocks; encouragingly, despite taking on water, many stocks are still hanging in there. That said, you also shouldn’t be complacent—after four months with no meaningful pullbacks, it’s likely (not for sure, but likely) the market needs more than six trading days to consolidate the January-April advance. In a nutshell, you should keep tight stops in place on losers and laggards, give your profitable names a bit more rope and, on the buy side, be very selective and/or keep positions small. We’re moving our Market Monitor down to a level 5.

Interestingly, this week’s list is very heavy on growth-y names despite the market’s plunge. Our Top Pick is Match.com (MTCH), which has a great long-term story, and the stock has re-emerged after earnings.

Stock Name	Price	Buy Range	Loss Limit
Avalara (AVLR)	102.00	64.5-67.5	56-58
HubSpot (HUBS)	582.89	170-175	157-160
Lithia Motors Inc. (LAD)	146.30	107-111	97-100
Match (MTCH)	0.00	66-69	58-60
PayPal (PYPL)	147.00	105-107.5	98-100
Roku, Inc. (ROKU)	150.46	74.5-77.5	64.5-66
Tandem Diabetes (TNDM)	74.77	60-63	54-55.5
Teradyne (TER)	82.83	44.5-46.5	42-43
TopBuild (BLD)	111.00	77.5-81	70-72
Woodward (WWD)	111.91	105-108	95-97

Current Market Outlook


After a punishing month, last week’s three-day bounce qualifies as a decent first step for the market and many individual stocks and sectors—most now have some breathing room above last week’s low points, and ideally, we’ll begin to see more potential leaders strut their stuff in the weeks ahead as the situation stabilizes. But a good first step is the best description we can give the bounce at this point given that the intermediate-term trends of just about everything (indexes, sectors, stocks) remain pointed down, and the odds favor plenty of volatility (at the very least) going forward. It’s not 2008 out there, but trends are negative, so until the bulls truly retake control, defense is the name of the game. We’re leaving our Market Monitor at a level 3.

The good news is that this week’s list has many recent earnings winners that could do well once a new uptrend gets underway. Our Top Pick is Exact Sciences (EXAS), a name we’re high on and that remains perched near its highs after another excellent quarterly report.

Stock Name	Price	Buy Range	Loss Limit
Bilibili (BILI)	28.71	13.3-14.5	11-12
Cooper Tire (CTB)	31.50	30.5-32.5	27.5-29
Deckers Outdoor Corp. (DECK)	141.68	126-131	114-117
Exact Sciences (EXAS)	116.91	70-74	63-65.6
HealthEquity, Inc. (HQY)	70.70	90-94	81-83.5
Keurig Dr Pepper (KDP)	25.35	25-26	22.5-23.5
Omnicell (OMCL)	81.03	66-69	61.5-62.5
Starbucks (SBUX)	64.49	62-64	56-57.5
Under Armour, Inc. (UAA)	26.82	22-23.5	20-20.9
VeriSign (VRSN)	190.71	157-162	145-149

Thank you for subscribing to the Cabot Undervalued Stocks Advisor. We hope you enjoy reading the January 2022 issue.



We comment on the abrupt shift in market sentiment that has boosted the prices of our undervalued stocks relative to expensive hyper-growth stocks. Several of our left-for-dead stocks, like Arcos Dorados (ARCO), which jumped 17% in the past two weeks, have suddenly been rediscovered by the market. Others, like Coca-Cola (KO) and Sensata Technologies (ST), are reaching new all-time highs as investors find that their healthy fundamentals haven’t been fully reflected in their share prices.



This shift may not last, and is only two weeks or so in the making. But it reinforces our view that, to quote Warren Buffett, “in the short run, the market is a voting mechanism, but in the long run it is a weighing mechanism.”



Please feel free to send me your questions and comments. This newsletter is written for you and the best way to get more out of the letter is to let me know what you are looking for.



I’m best reachable at Bruce@CabotWealth.com. I’ll do my best to respond as quickly as possible.

Thank you for subscribing to the Cabot Turnaround Letter. We hope you enjoy reading the March 2022 issue.



In what could be a low-return market over the coming decade, stocks of relatively boring companies have a better chance to shine. We highlight five companies with grind-it-out growth, low share valuations and often-generous dividends that could produce significant market-beating returns.



We also discuss six appealing stocks we found by trolling through the 13F/D filings of like-minded institutional investors.



Our featured recommendation this month is Goodyear Tire & Rubber Company (GT). An investment in Goodyear is an opportunistic purchase of an average company whose shares have fallen sharply out of favor for what look like short-term reasons.



We note our recent price target increases for Wells Fargo (WFC), Marathon Oil (MRO) and Shell plc (SHEL).